Marshall Wace LLP Purchases New Holdings in Artivion, Inc. (NYSE:AORT)

Marshall Wace LLP acquired a new position in shares of Artivion, Inc. (NYSE:AORT) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 14,277 shares of the company’s stock, valued at approximately $366,000.

Other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in shares of Artivion by 38.6% during the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after buying an additional 505 shares in the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Artivion by 3.1% in the 2nd quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock valued at $510,000 after purchasing an additional 600 shares during the period. Texas Permanent School Fund Corp lifted its position in shares of Artivion by 2.0% in the first quarter. Texas Permanent School Fund Corp now owns 34,129 shares of the company’s stock worth $722,000 after purchasing an additional 677 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Artivion in the second quarter worth approximately $28,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Artivion by 5.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock worth $713,000 after purchasing an additional 1,634 shares during the period. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AORT has been the topic of several research reports. Oppenheimer upped their price objective on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Lake Street Capital increased their price objective on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Needham & Company LLC reissued a “buy” rating and set a $30.00 price objective on shares of Artivion in a research report on Friday, September 27th. Finally, Stifel Nicolaus upped their target price on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th.

Artivion Stock Performance

Shares of AORT opened at $25.44 on Friday. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -106.00 and a beta of 1.74. The company’s fifty day moving average is $25.58 and its 200-day moving average is $24.22. The company has a quick ratio of 4.04, a current ratio of 5.63 and a debt-to-equity ratio of 1.07. Artivion, Inc. has a 12 month low of $12.16 and a 12 month high of $29.24.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The firm had revenue of $98.02 million for the quarter, compared to the consensus estimate of $97.70 million. Equities analysts expect that Artivion, Inc. will post 0.2 EPS for the current fiscal year.

Insider Activity

In other news, CAO Amy Horton sold 12,430 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now directly owns 139,989 shares in the company, valued at approximately $3,664,912.02. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Artivion news, SVP Jean F. Holloway sold 3,167 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.55, for a total value of $84,083.85. Following the sale, the senior vice president now owns 161,932 shares of the company’s stock, valued at $4,299,294.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the transaction, the chief accounting officer now directly owns 139,989 shares in the company, valued at approximately $3,664,912.02. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,109 shares of company stock valued at $951,935. Insiders own 8.10% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.